Navigation Links
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Date:2/27/2008

have had no treatment options, as patients in the clinical trial on everolimus experienced a significantly longer period of time during which their cancer did not progress," said Daniel Vasella, Chairman and CEO of Novartis. "Everolimus is a targeted therapy which is being studied in multiple tumor types, and could provide significant benefit to patients suffering from cancer."

"This progression-free survival benefit demonstrates the possibilities of continuous mTOR inhibition as a promising target in oncology," said David Epstein, President and CEO, Novartis Oncology. "These data are the first from a broad clinical research program that includes studies in patients with high unmet needs suffering from a variety of cancers. Everolimus is the first compound in our dynamic oncology late-stage pipeline with six compounds in registration trials to show exciting clinical data this year."

Complete results of the RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) trial will be submitted as a late-breaking abstract for presentation at the American Society of Clinical Oncology annual meeting in May. Worldwide regulatory filings for this indication beginning with US and EU will occur in the second half of 2008.

RECORD-1 is the largest Phase III trial to investigate the potential of the oral mTOR inhibitor everolimus as a treatment option for patients with metastatic RCC who have failed prior targeted therapy. The randomized, double- blind multi-center Phase III study compared everolimus to placebo.

Patients in the study were randomized according to Memorial Sloan- Kettering Cancer Center (MSKCC) risk criteria and prior anti-cancer therapy. MSKCC risk criteria are standard clinical criteria to determine the prognosis of patients with RCC.

In addition to RCC, everolimus is presently being evaluated in neuroendocrine tumors, lymphoma, other cancers, and tuberous sclerosis as a single agent or in combination with existing cance
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
5. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
6. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
7. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
(Date:11/26/2014)... WASHINGTON and NEW YORK ... 2014 As the leading distributor of market ... a new research report by IQ4I Research and Consultancy ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast ...
(Date:11/26/2014)... Nov. 25, 2014  At the American Dental Association,s ... this October, KaVo Kerr Group was honored to be ... attendees the opportunity to see and test the Best ... leaders deliver lectures on the latest developments in dental ... the new DEXIS CariVu Caries Detection Device and Kerr ...
Breaking Medicine Technology:Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... SUNNYVALE, Calif., Nov. 10, 2011 Accuray Incorporated (Nasdaq: ... that its president and chief executive officer, Euan S. Thomson, ... 8th Annual Healthcare Conference in New York City on Tuesday ... Thomson is also scheduled to present at the Stephens Fall ...
... healthcare distributors continue to provide increased value to the ... challenges in the pharmaceutical industry, according to The ... released by the Center for Healthcare Supply Chain Research. ... Healthcare Distribution Management Association (HDMA).   ...
Cached Medicine Technology:Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 2Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 3Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 4
(Date:11/28/2014)... November 28, 2014 Dr. Paul Vitenas, one of ... a Glitter & Glow Holiday Event for those in the area ... at his practice. Glitter & Glow will take place on December ... new location in the heart of Houston at 4208 Richmond Ave. ... and hope that you will come and celebrate the season with ...
(Date:11/28/2014)... 2014 Written and narrated by award winning ... releases the “The Happiest Man In the World: Life ... of how and why Project C.U.R.E. came to be. , ... Josie and the Reverend Richard W. Jackson, Dr. Jackson exceeded ... 30, but realized that he wasn’t happy. Prompted by this ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter , ... in the kitchen, through cooking classes or at home, may ... a recent review. Cooking programs and classes for children ... to the new research. And, although the review didn,t look ... such programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 An inventor and ... light on a patient’s filling and it was almost impossible ... ergonomic curing light," she said. , The patent-pending Access Light ... eases access to areas of the mouth, as well as ... efficiency and safety. Easy to use and clean, it also ...
(Date:11/28/2014)... New York, New York (PRWEB) November 28, 2014 ... lawsuits ( http://www.consumerinjurylawyers.com/stryker-rejuvenate/stryker-hip-lawsuits/ ) have now been filed ... pair of recalled metal implants, Bernstein Liebhard LLP ... November 18th in Bergen County Superior Court reflects ... and ABG II modular-neck hip stems, which were ...
Breaking Medicine News(10 mins):Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3
... of OTC drugs grew by 2.4% from $17.8 million ... the latest research in Nonprescription Drugs USA 2008: ... research firm Kline & Company.Private-label OTC medicines were up ... and allergy medicines posted the highest growth last year, ...
... sensitive gradiometer instrument has been switched on and is ... is specifically designed to measure Earth,s gravity field with ... we have seen from the gradiometer from the moment ... working in very good health and provide meaningful data," ...
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), ... that it has scheduled a conference call and web cast ... discuss operating results for the first quarter ended March 29, ... morning of April 30 before pre-market trading. The conference call ...
... Super Bowl MVP Eli Manning , who serves ... business and corporate leaders on Monday, April 6, for a private ... and a member of the March of Dimes NY Division Board ... 3 Times Square, in New York. CBS 2 News Co-Anchor, Maurice ...
... ATLANTA, April 8 Amoena, the worldwide ... the introduction of The Hannah Collection, the ... E and Aloe to ease discomfort after ... )(Photo: http://www.newscom.com/cgi-bin/prnh/20090408/CL96087 ...
... MYL ) today announced the settlement of all ... generic version of Schering- Plough,s Clarinex(R) allergy medication. This ... of New Jersey since September 2006.Pursuant to the settlement, ... 5 mg, in the U.S. on July 1, 2012, ...
Cached Medicine News:Health News:Private-label OTC Drugs Post Solid Gains in 2008, According to Kline 2Health News:Private-label OTC Drugs Post Solid Gains in 2008, According to Kline 3Health News:GOCE's 'heart' starts beating 2Health News:Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, April 30, 2009 2Health News:Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, April 30, 2009 3Health News:Eli Manning and Top Corporate Leaders Rally to Help Save Babies 2Health News:Amoena Introduces First Post Surgical Garments With Vitamin E & Aloe to Help Soothe and Comfort After Breast Surgery 2Health News:Mylan Announces Clarinex(R) Settlement Agreement 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: